Navigation Links
Procainamide & NAPA

ProductsProcainamide & NAPA
Company ARUP Laboratories
Item Procainamide & NAPA
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Drugs of Abuse Array Cocaine Metabolite Assay
2. Amiodarone & Metabolite
3. Amoxapine & Metabolite, Serum or Plasma
4. Amoxapine & Metabolite, Urine
5. Antabuse Disulfiram (DEDTC Metabolite) Quantitation, Serum or Plasma
6. Antabuse, Disulfiram (DEDTC Metabolite) Quantitation, Urine
7. Bupropion & Metabolite
8. Clomipramine & Metabolite
9. Cocaine & Metabolites Detection
10. Cocaine MetabolitesConfirmation/Quantitation, Meconium
11. Cocaine Metabolite (Benzoylecgonine) Confirmation/Quantitation, Urine
ApexPro CH
ISI Alumi-Hand
TeleRehab™ Advantage
ISI Ultra-Light Specialty Table
Medicine Products:
(Date:11/20/2009)...ire-USNewswire/ -- The American Dental Association...ration (FDA) to establish appropriate classificati...oncern about the safety of whitening products that...fessional consultation or examination by a dentist...mically based tooth whitening or bleaching agents ...
(Date:11/20/2009)...wire-USNewswire/ -- The following is a statement b...Health Care Association: ,, "The Nevada Health ... Majority Leader Harry Reid for his leadership in ... protecting every Nevada seniors, ongoing access t...rength and viability of our state,s vital frontlin...
(Date:11/20/2009)...ildren with chronic kidney disease often fail to d...sits increasing a child,s risk for serious heart ... Children,s Center and other institutions. A repor... American Society of Nephrology. , Researchers...ing regular doctor visits to readings obtained via...
(Date:11/20/2009)...g 90-day supply, study finds , , FRIDAY,...supply of prescription drugs is up to one-third ch... a new study. , U.S. researchers analyzed 26,85...and 2005, and found that patients who bought a thr...d an average 29 percent in out-of-pocket costs. Af...
(Date:11/20/2009)...es increased food insecurity as many face problem ...swire/ -- Project Bread, the state,s leading anti-...oming annual status report on hunger in the Common...eport, caused by high unemployment, point to 554,0...er. Food insecurity has found its way into middle ...
Breaking Medicine News(10 mins):Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4
..., Nov. 1 Arete Therapeutics Inc. today,announced ... lead compound,AR9281, for the treatment of hypert...e inhibitor of soluble epoxide hydrolase (s-EH), a...armacokinetics and pharmacodynamics for single asc...
... Nov. 1 Amedica Corporation, an,orthopedic implan...nologies, announced today that Ashok Khandkar, Ph....ice President Finance and Chief Financial,Officer,... Hotel in New York City. Mr. Khandkar and Mr. Gal...
...gland and PHILADELPHIA, November 1, Shire plc (LSE...ty biopharmaceutical company announces results for...ghts - Product sales up 41% to $543.1 million; -...ed to be at least 30% (Q2 guidance: at,least 25%)....
...nfirm environmental toxins play role in autism, as..., Nov. 1 The National Autism,Association (NAA) an...school districts to implement the "Greening Your S...nate the serious,dangers posed to children from da...
...wth Over Same Quarter Last Year - - 20%... - FY08 Revenue Projection Raised - ...ed - - Conference Call to be Held at 10:00 a.m....cal 2008 ended September 30, 2007, up 73% from $1....
...Calif., Nov. 1 The Maverick Saloon will,host a tr...ber 8, 2007 from,4 PM until 7 PM to raise research... that claimed the life of the much loved and respe...yvjoneshouse.com . The proceeds from the show wil...
Other Medicine News:Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 31Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 32Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 33Health News:National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National 'Greening Your School' Initiative 2
(Date:11/20/2009)...ov. 20 Soligenix, Inc. (...y), formerly known as DOR BioPharma, Inc., a late-...it has formed a consortium to develop thermostable... acting vaccines. Soligenix received a $9.4 millio... Infectious Diseases (NIAID), a division of the Na...
(Date:11/19/2009)...ov. 19 In a series of ne..., Heska Corporation (Nasdaq: HSKA ) ("Heska" or t...w and improved website. The upgraded site is the ...rogramming to align the site with the company,s ne...go: http://www.newscom.com/cgi-bin/prnh/20000622...
(Date:11/19/2009)...Nov. 19 The D e al m...its Most Admired Corporate Dealmakers for the seco... its Most Admired Dealmaker in pharma/biotech for ...nd divestitures since January 2006. ,, Over the...tfolio with a focus on high-growth, innovation-dri...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Response Times Vary for In Hospital Heart Attacks 53388 1Response Times Vary for In Hospital Heart Attacks 53388 2Blood Transfusions Not Linked to Long Term Problems 53386 1JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 1JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 2JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 3JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 4